Migraine medication Frova (frovatriptan) is indicated for the acute treatment of migraine attacks with or without aura in adults.
Migraine medication Frova (frovatriptan) is not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine. The safety and effectiveness of Frova (frovatriptan) have not been established for cluster headache, which is present in an older, predominantly male, population.
The most common Frova side effects associated with use of Frova migraine medication are: <br>
* dizziness <br>
* fatigue (tiredness)<br>
* headache (other than a migraine headache)<br>
* paresthesia (feeling of tingling)<br>
* dry mouth <br>
* flushing (hot flashes) <br>
* feeling hot or cold <br>
* chest pain <br>
* dyspepsia (indigestion) <br>
* skeletal pain (pain in joints or bones)<br>
Tell your doctor about any Frova side effects that you develop. If you feel Frova side effects like dizziness or fatigue, take extra care or avoid driving and operating machinery.In very rare cases, patients taking this class of medicines experience Frova side effects like serious heartproblems, stroke, or increased blood pressure. If you develop Frova side effects like pain, tightness, heaviness,or pressure in your chest, throat, neck, or jaw, contact your doctor right away.Also contact your doctor right away if you develop Frova side effects like a rash or itching after taking FROVA. You may experience Frova side effects.
Frova Information :Frova migraine medication should not be given to patients with ischemic heart disease (e.g. angina pectoris, history of myocardial infarction, or documented silent ischemia), or to patients who have symptoms or findings consistent with ischemic heart disease, coronary artery vasospasm, including Prinzmetal’s variant angina or other significant underlying cardiovascular disease. FROVA should not be given to patients with cerebrovascular syndromes including (but not limited to) strokes of any type as well as transient ischemic attacks. FROVA should not be given to patients with peripheral vascular disease including (but is not limited to) ischemic bowel disease.
Frova migraine medication should not be given to patients with uncontrolled hypertension. FROVA should not be used within 24 hours of treatment with another 5-HT1 agonist (e.g. Imitrex, Zomig, Maxalt, Relpax, an ergotamine containing or ergot-type medication such as dihydroergotamine (DHE) or methysergide. FROVA is contraindicated in patients who are hypersensitive to frovatriptan or any of the inactive ingredients in the tablets.